Recent

% | $
Quotes you view appear here for quick access.

ADVENTRX Pharmaceuticals, Inc. Message Board

  • leonia5pbb leonia5pbb Feb 21, 2013 10:12 PM Flag

    Why only 2% insider ownership? ANX

    Very low insider ownership here, why?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • by mp3dotcombaby Oct 25, 2012 5:29 PM - "Going to take 24 months for the trial, then another 6 months minimum for NDA."
      "Estimated Primary Completion Date: December 2014"
      "ClinicalTrials.gov processed this record on February 21, 2013"

      ClinicalTrials.gov Identifier: NCT01737814
      This study is currently recruiting participants.
      Verified January 2013 by Adventrx Pharmaceuticals
      Sponsor: Adventrx Pharmaceuticals
      First received: November 27, 2012
      Last updated: January 30, 2013
      Last verified: January 2013

      The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

      Estimated Enrollment: 388
      Study Start Date: January 2013
      Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

      ClinicalTrials.gov processed this record on February 21, 2013

    • According to website, secform4, and Yahoo Finance Summary - Major Holders, Brian Culley :
      2012-03-13
      Purchase 14,000 shares Average price $0.5817
      2012-03-14
      Purchase 20,500 shares Average price $0.5904

      Shares Ownership 34,500 (Direct)

      Per 10-Q filed on 11/05/2012 - 47,715,709 shares issued and outstanding at both September 30, 2012 and December 31, 2011

      34,500 / 47,715,709 = 0.000723032 i.e. 0.072303232%

 
ANX
0.0000(0.00%)